News & Events

Learn about what's new with CMC Biologics

AGC Asahi Glass Signs Agreement to Acquire CMC Biologics


CMC Biologics to continue to provide CDMO services to the biopharma marketplace


Bothell, WA, Copenhagen, Denmark, Berkeley, CA, and Tokyo, Japan– December 19, 2016 – CMC Biologics, a global leader in clinical and commercial manufacturing of monoclonal antibodies, coagulation factors and other therapeutic proteins and AGC Asahi Glass (AGC), a world-leading manufacturer of glass, chemicals and high-tech materials, announced today that they have entered into a definitive agreement with CMC Biologics’ shareholders including Monitor Clipper Partners, European Equity Partners and Innoven Partenaires, by which AGC will acquire 100% of CMC Biologics’ shares. This acquisition is expected to close in January 2017. 

View or Download as a PDF  

Follow Us
Join us on LinkedIn Follow us on Twitter